Boston Immune Technologies and Therapeutics and BeiGene Enter into an Exclusive Option and License Agreement to Develop Novel TNFR2 Antagonists
Exclusive license for Asia (ex-Japan), Australia and New Zealand; Parties plan to conduct combination studies with BeiGene's anti-PD-1 antibody tislelizumab...






